Innovations + Investments in Healthcare Summit 2015


LundbeckH. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs today approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2009, the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD 2.6 billion). For more information, please visit

Lundbeck RSS Channel

Title Filter      Display #  
# Article Title
1 Kåre Schultz appointed new president and CEO of Lundbeck
2 Lundbeck and Otsuka to co-develop Lu AF20513, an investigational vaccine against Alzheimer's disease
3 The solid momentum continues - New Products up by 41%
4 Takeda and Lundbeck announce FDA approval of Brintellix™ (vortioxetine)
5 Vortioxetine, a new multimodal agent in development for the treatment of major depression
6 Lundbeck is well on track to deliver on guidance for 2013
7 Lundbeck announces positive results for Brintellix™ (vortioxetine)
8 Lundbeck and Otsuka further expand their alliance and enter into collaboration
9 Lundbeck on track to meet financial expectations and renew its product portfolio
10 Lundbeck's Lu AE58054 meets primary endpoint
11 Statistically significant clinical phase III results of Lu AA21004
12 Lundbeck and Otsuka Pharmaceutical sign historic agreement
13 Lundbeck's third quarter report 2011 - The positive momentum continues
14 Lundbeck's first half report 2011
15 Lundbeck's partner Mochida receives approval of Lexapro in Japan
16 A new pharmaceutical candidate enters Lundbeck's development pipeline
17 Lundbeck delivers at the top-end of guidance and momentum is expected to continue in 2011
18 The clinical phase III programme commenced on zicronapine
19 First two clinical phase III studies confirm the profile of nalmefene
20 Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]